Archford Capital Strategies LLC Acquires 4,331 Shares of Johnson & Johnson $JNJ

Archford Capital Strategies LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 47.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,475 shares of the company’s stock after acquiring an additional 4,331 shares during the quarter. Archford Capital Strategies LLC’s holdings in Johnson & Johnson were worth $2,498,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Norges Bank bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $4,877,174,000. Laurel Wealth Advisors LLC grew its position in Johnson & Johnson by 15,040.6% in the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after acquiring an additional 7,371,687 shares in the last quarter. Vanguard Group Inc. increased its stake in Johnson & Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in Johnson & Johnson during the second quarter worth about $401,420,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.3%

NYSE:JNJ opened at $206.93 on Wednesday. The firm has a market capitalization of $498.56 billion, a P/E ratio of 19.97, a P/E/G ratio of 2.25 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average of $200.25 and a 200 day moving average of $181.93. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Morgan Stanley raised their price objective on Johnson & Johnson from $190.00 to $197.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Royal Bank Of Canada set a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 17th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. UBS Group increased their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Finally, Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Four analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $211.25.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.